Adavosertib
Undifferentiated Ovarian Carcinoma
Explore 11 assets in Undifferentiated Ovarian Carcinoma →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02101775CT.gov Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Undifferentiated Ovarian Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adavosertib (this asset) | National Cancer Institute (NCI) | P2 | CCC · 52 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P3 | BB |
| Olaparib | National Cancer Institute (NCI) | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Gynecologic Oncology Group | P3 | BB |
| Nogitecan | National Cancer Institute (NCI) | P2/3 | BB |
| Docetaxel | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | B |
+24 more in the Undifferentiated Ovarian Carcinoma cohort
Other indications for Adavosertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Refractory Malignant Neoplasm | — | P2 | B · 62 |
| Female Reproductive Organ Cancer | — | P2 | B · 59 |
| Exocrine Pancreatic Carcinoma | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adavosertib in Undifferentiated Ovarian Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/adavosertib-undifferentiated-ovarian-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →